CAC 40
7 966,19 -78,92 (-0,98 %) Euro Stoxx 50
4 936,77 -47,71 (-0,96 %) Dow Jones
37 735,11 -248,13 (-0,65 %) EUR/USD
1,0648 +0,0023 (+0,21 %) Gold future
2 388,50 +5,50 (+0,23 %) Bitcoin EUR
59 186,83 -2 885,40 (-4,65 %)
Oxford Nanopore Technologies plc (ONT.L)
Oxford Nanopore Technologies plc
Gosling Building
Edmund Halley Road Oxford Science Park
Oxford OX4 4DQ
United Kingdom
44 84 5034 7900
https://nanoporetech.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 1 238
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Dr. Gurdial Singh Sanghera | Co-Founder, CEO & Non-Executive Director | 1,59M | S.O. | 1961 |
| Mr. Timothy Cowper | COO & Director | 894,98k | S.O. | 1965 |
| Dr. James Spike Willcocks | Chief Strategy Officer & Director | 1,19M | S.O. | S.O. |
| Prof. Hagan Bayley Ph.D. | Co-Founder & Member of Technical Advisory Board | S.O. | S.O. | S.O. |
| Mr. Nicholas Patrick Keher | CFO & Director | S.O. | S.O. | 1982 |
| Mr. Jordan Herman | Senior VP & General Counsel | S.O. | S.O. | S.O. |
| Mr. John Schoellerman | Senior Vice President of Corporate & Business Development | S.O. | S.O. | S.O. |
| Mr. Richard Compton | Senior Vice President of Sales & Commercial Operations | S.O. | S.O. | S.O. |
| Ms. Sara Agee Le | Vice President of Global Marketing | S.O. | S.O. | S.O. |
| Ms. Sarah Lapworth | Senior Vice President of Global Human Resources | S.O. | S.O. | S.O. |
Description
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a nanopore based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company operates in Life Science Research Tools and Covid Testing segments. It offers MinION, a portable device for DNA and RNA; GridION, a flexible and self-contained benchtop nanopore sequencer to run and analyse up to five MinION or Flongle flow cells; MinION Mk 1C, a nano pore-based sequencer with analysis software and connectivity for self-contained and portable sequencing; Flongle, an adapter for MinION or GridION that enables DNA sequencing or cDNA sequencing on smaller and single-use flow cells; and PromethION 2 Solo, a sequencer for two PromethION flow cells. The company also provides PromethION 2, a self-contained benchtop nanopore sequencer; PromethION 24, which provides single or multiple users with access to terabases of sequencing data; PromethION 48, a sequencing device with high-output flow cells; VolTRAX, an automated library prep for nanopore analyses; and Q-Line, a sequencing for applied applications, as well as products for SAR-Cov-2 testing. Its platform enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Oxford Nanopore Technologies plc en date du 1 avril 2024 est 8. Les scores principaux sont Audit : 3; Société : 8; Droits des actionnaires : 9; Compensation : 8.
